MedTrace Logo

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

NCT04948151 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2021-07-01

No results posted yet for this study

Summary

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.

Conditions

  • Female Sexual Arousal Disorder

Interventions

DRUG

Sildenafil

Patients will apply 2-gram applications up to 9 times per month.

DRUG

Placebo

Patients will apply 2-gram applications up to 9 times per month

Sponsors & Collaborators

  • Daré Bioscience, Inc.

    collaborator INDUSTRY

  • Strategic Science & Technologies, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2021-12-15
Completion
2021-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948151 on ClinicalTrials.gov